Latest MS News
BEYOND Study News Release
Click here for Understanding the BEYOND Study Results
New Survey Finds Technology Plays a Critical Role in the Lives of People with Multiple Sclerosis
First of its Kind Data Show: Immediate Treatment of Early MS Patients with BETASERON Significantly Delayed Permanent Disability
Early treatment with Betaseron significantly delayed the time to a second clinical event
Marathon Runner Completes Inspiration Goal of 12 Races in 12 Months
Multiple Sclerosis: Long-Term Follow-Up Study Underscores Proven Benefits of BETASERON Treatment
Multiple Sclerosis No Obstacle for Cross-Country Cyclist with A Mission
Download
BETASERON® (Interferon beta-1b) is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.
Important Safety Information
The most commonly reported adverse reactions are lymphopenia, injection-site reaction, asthenia, flu-like symptom complex, headache and pain. Gradual dose titration and use of analgesics during treatment initiation may help reduce flu-like symptoms. BETASERON should be used with caution in patients with depression. Injection-site necrosis has been reported in 4% of patients in controlled trials. Patients should be advised of the importance of rotating injection sites. Female patients should be warned about the potential risk to pregnancy. Cases of anaphylaxis have been reported rarely. See "Warnings," "Precautions," and "Adverse Reactions" sections of full Prescribing Information.
